Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
42.50    -2.50 (-5.56%)
Bid:
42.00
Ask:
43.00
Spread: 1.00 (2.381%)
Market Cap: £81.54m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q4 2024 Update

23 Jan 2025 07:00

RNS Number : 3668U
Iofina PLC
23 January 2025
 

23 January 2025

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM: IOF)

 

Q4 2024 Corporate Update

Record Full Year 2024 Iodine Production & IO#11 On Track

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides a brief update regarding its activities during Q4 2024 and an outlook for 2025.

 

In Q4 2024, Iofina Resources produced 194.1 metric tonnes (MT) of crystalline iodine from its seven IOsorb® plants in western Oklahoma, a Q4 record for Iofina. Iofina's seventh operating plant, IO#10, has achieved full iodine production from September 2024.

 

The total H2 2024 production of 358MT was within our forecast range. When combined with H1 2024 crystalline iodine production of 276.1MT, total production for the year was a record for the Company, up 13.4% to 634.1MT compared to 2023 production of 559.3MT.

 

The Company has benefitted from a strong spot raw iodine price in excess of H1 2024 levels and is currently above $70/kg. Prices are anticipated to remain at these higher levels throughout H1 2025 due to the continued robust global demand for iodine. IPBC product sales have performed particularly well for Iofina Chemical in 2024, significantly surpassing 2023 levels, driven by strong interest from customers.

 

In December 2024, confirmed sales of more than $2.0m, which had been dispatched to customers from the Iofina Chemical facility, were unexpectedly delayed due to cargo shipping and logistical issues beyond the Company's control. In line with the Group's accounting policies, these orders will now be credited as sales in January 2025. Consequently, the Group expects to report adjusted EBITDA for 2024 in the region of $7.5m, below the forecast range of $8.5m-$9m. The Company projects that without these unexpected delays, the Group would have met its forecasted adjusted EBITDA target range. The recognition of delayed sales in January 2025 has given the Group a stronger start to the year than previously forecast.

 

With IO#9 and IO#10 operating as expected, along with the legacy plants, we are forecasting total iodine production for H1 2025 in the range of 320MT-355MT (H1 2024: 276.1MT). The Group notes that, as usual, production will be weighted to the second half when warmer brine water temperatures and larger brine volumes improve efficiencies and total iodine output.

 

The Company's growth strategy remains firmly on track. Construction has begun for IO#11 in Iofina's newest core area, with the initial land work underway and major components in the process of being supplied. The plant is expected to be completed and operational in Q3 2025. Preliminary discussions regarding IO#12 are progressing positively, further demonstrating the Company's commitment to expanding and accelerating its production capabilities.

 

Finally, the Group continues its proud record of ensuring a safety-first approach throughout its operations and reports that it has had no lost time incidents since April 2021.

 

President and CEO, Dr. Tom Becker, commented:

"The Company, as expected, achieved record iodine production in 2024. Our business operations have gone from strength to strength throughout 2024 with the successful completion of our new plant IO#10, which is operating as expected, as well as strategic investment at Iofina Chemical. With the foundations for IO#11 currently being laid, we are on track to complete construction in Q3 2025. At the same time, we are making good progress in finalising plans for IO#12. These developments highlight our ongoing focus on rapidly executing our growth strategy in a prudent fashion.

 

"Whilst the December shipping delays to customers were certainly frustrating in terms of hitting our year-end earnings target, we are pleased with the Group's overall performance in FY24. These delayed sales have been recognised in January 2025, which underpins our forecast for 2025. With iodine prices currently above $70/kg, and expected higher iodine production compared to 2024, the current outlook for the year is very promising."

 

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

 

Enquiries:

 

Iofina plc

Dr. Tom Becker

CEO & President

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Canaccord Genuity Limited

Henry Fitzgerald-O'Connor/Harry Rees

Tel: +44 (0)20 7523 8000

 

Financial PR and Media Contact:

Yellow Jersey PR Limited

Charles Goodwin/Shivantha Thambirajah/Zara McKinlay

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

 

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina operates seven IOsorb® plants in Oklahoma and consistently uses technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high-quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFIFLEIFFIE
Date   Source Headline
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.